Transcript Some Closing Remarks

Some Closing Remarks
Scope of Symposium
• Simultaneous Worldwide Development Strategies &
Pharmacogenomics: 6 Sessions
– 1. Overview: Drs. Yazaki; Fujiwara, Wu, Jang, Malhotra,
Murasake, Ishigooka, Hayashi, Kato, Kuemer
– 2. New Challenges: Drs. Imura, Tanigawara, Takei, Boyle,
Nagata, Shimatani
– 3. ICHE5: Drs. O’Neill, Farrell, Loew, Ferris, Lewis, Ono
– 4. More Conrete Plans/Actions based on ICH and APEC report:
Drs. Takeuchi, Azuma, Iwasaki,hi,Wood
– 5. Pharmacogenomics: drug discovery/development based on
genetic analysis: Drs. Kamataki, Nihira, Riddell, Rakin, Horii,
Sasai, Gushima
– 6. Implementation of Global Development Programs: Drs.
Doogan, Uden, Kurokawa, Gans
Excellent Presentations and Discussion
• Too little time to review each session
• Will try to synthesize discussions Much progress in evolution of ICH
E5 issues and initial experience in bridging studies
• Important distinction between Bridging versus Simultaneous Global
Strategies:
– Bridging: serial, evaluating and expanding existing information for
evaluation of risks/benefits of a drug in a new region
– Simultaneous: concurrent studies; presumably all regions will benefit
from each study
• Potential to shorten time needed for worldwide availability of effective new
drugs
• Likely to require fewer resources
• => Bridging studies likely to be less needed as legacy drugs are
evaluated more fully; simultaneous worldwide development will play a
greater role.
Premise
KEY PREMISE: Timely approval of effective drugs, and non-approval
of drugs that are ineffective or unacceptably toxic are the goals. In
some ways, these can be seen as competing with one another: the
latter suggests extreme caution prior to approval. Yet delays in process
may also delay the availability to the public of effective and safe drugs.
This makes regulators role especially challenging.

We must maintain high standards yet constantly look for ways of
expediting evaluation of drugs
 Bridging studies are by their nature imply a sequential versus
simultaneous development/evaluation strategy. Whenever
possible, simultaneous studies will produce information more
quickly and be beneficial to a broader audience since bridging
studies really only intended to help the new region.
Many Remaining Challenges
• Group into 3 broad & overlapping categories:
– Scientific
– Regulatory
– Infrastructure
Some Scientific Challenges
• Deeper understanding of ethnic differences in disease rates and
responsiveness to treatment: explainability via genomic
information will have substantial advantages in understanding the
role of a new treatment
• Bridging Studies
- when is a bridging study necessary?
- how large should a PK bridging study be?
- how large should a PK/PD study be?
• Simultaneous worldwide studies
-one versus several simultaneous studies
-minimal sample size per participating country?
-2 primary endpoints that individual countries weigh
differently with respect to approval?
• Pharmacogenomics: initial role: explaining apparent associations (eg,
ethnicity) at a more causal level; identifying patient subgroups who are
more/less likely to benefit from treatment or have an AE
Some Infrastructure Challenges
-Greater engagement by physicians in trials
- availability of physician time
- appreciation of clinical research in
academia
- physician training in clinical research and
issues
-Familiarity in data management; QA/QC
- adequate expertise
- adequate time
-Familiarity with working together in multicenter
studies: common procedures, assay methods
Some Regulatory Challenges
• Challenges to regulators are formidable
• Need to reach common agreement on a study’s
design, its conduct, and how it will be analyzed.
• Shortage of MO and statisticians limits both
design of multinational trials as well as review of
their results.
– Numbers of MOSs/statisticians in regulatory agencies
in Japan, Taiwan, Korea is woefully low.
– Need to increase substantially and make the work
challenging and interesting to attract and retain high
quality physicians/statisticians.
Next Steps
1. Continued research into designs for and analyses of
multinational trials and bridging studies:
– a. how much evidence is needed about safety, efficacy, doseresponse in each participating country? Will vary with disease,
type of drug, knowledge of drug class, prior beliefs on whether
treatment efficacy varies among subpopulations.
– b. designing several trials that can be simultaneously conduct
i. Study 1: Phase III; regions 1, 2, 3
ii. Study 2: Phase III (confirmatory); in regions 2,4,5
iii. PK substudies versus separate studies in same/other
regions
iv. How much flexibility in concomitant meds; criteria
for dose modification based on side-effects, etc among
participating countries
2. Pharmacogenomics: combine genetic information with
other to see if apparent associations between ethnicity and
outcome variables explainable by genetic information
Next Steps (continued)
3. Training: develop greater expertise in clinical research
studies among academia physicians engaged in research
4. Regulatory:
-increase number of medical officers and statisticians
to improve quality and speed of review process
-promote interactions among regulators from different
countries (eg, Asian countries) in hopes of identify
commonality in how bridging and simultaneous global
studies can be conducted.
Thank you for attending and participating!!